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Information on gene alterations associated to poorly differentiated (PDTC) and anaplastic thyroid carcinomas (ATC) is scarce. Using
human cancer cell lines as a tool for gene discovery, we performed a cytogenetic and oligo-array analysis in five new cell lines derived
from two PDTC and three ATC. In PDTC we evidenced, as important, the involvement of the MAPK/ERK kinase pathway, and
downregulation of a group of suppressor genes that include E-cadherin. In ATC, downregulation of a specific group of
oncosuppressor genes was also observed. Our ATC cell lines presented chromosomal markers of gene amplification, and we were
able to identify for the first time the nature of the involved amplicon target genes. We found that the main molecular differences
between the two cell line types were related to signal transduction pathways, cell adhesion and motility process. TaqMan
experiments performed for five amplicon target genes and for two genes, which allowed a clear distinction between ATC and PDTC:
CDH13 and PLAU corroborated array results, not only in the cell lines, but also in an additional set of primary 14 PDTC and three
ATC. We suggest that our findings may represent new tools for the development of more effective therapies to the hitherto
untreatable ATC.
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Thyroid malignant neoplasms of follicular cell origin are classified
into four main categories: the differentiated papillary (PTC) and
follicular (FTC) carcinomas, the poorly differentiated (PDTC) and
the undifferentiated or anaplastic (ATC) carcinomas. The differ-
entiated forms are the most common. Poorly differentiated thyroid
carcinomas and ATC account for only 5–10% of the follicular
malignancies; however, although rare, they represent a major
challenge in oncology as they have a high morbidity and mortality
rate (DeLelllis and Williams, 2004).
In recent years some progress has been obtained in the
identification of the genomic changes associated to the pathogen-
esis of DTC. In PTC, it is now clear that, in a substantially fraction
of tumours, malignant transformation takes place through the
constitutive activation of effectors along the MAPK/ERK kinase
pathway (Mellilo et al, 2005), and in FTC, the PAX8/PPRAg fusion
gene was determined to be an important event in the development
of a subset of these carcinomas (Lacroix et al, 2005). At variance,
the genetic information concerning PDTC and ATC is very limited.
Only 27 PDTC have been evaluated by comparative genomic
hybridisation (CGH) analysis, and as far as we are aware, there are
no microarray studies on this entity (Wreesmann et al, 2002;
Rodrigues et al, 2004). In ATC, it was demonstrated that TP53
(Wynford-Thomas, 1997) and b-catenin (Garcia-Rostan et al,
1999) mutations as well as the overexpression of OEATC1
(Mizutani et al, 2005) and AURKB (Sorrentino et al, 2005) were
associated with ATC phenotype. These genes were demonstrated to
be key effectors in anaplastic transformation, being responsible for
evasion to apoptosis, enhanced tumour growth and replicative
potential. However, although all efforts made, the molecular events
related to their high invasion capacity, sustained angiogenesis and
therapeutic resistance remain to be identified. By chromosomal
studies it has become clear that these neoplasms were frequently
characterised by cytogenetic markers of gene amplification: double
minutes (dm) and homogeneously staining regions (hsr) (Roque
et al, 1998). In other tumour types, such as neuroblastomas, the
evaluation of these markers allowed the identification of specific
oncogenes as targets of the amplification process, being found to
be associated with a more aggressive biologic behaviour (Brodeur,
2003). In ATC, the identification of the amplified target genes has
not been accomplished yet.
Cancer cell lines represent a pool of cells with an unlimited
renewal and proliferative potential, and have proven to be
invaluable in the research of aggressive rare tumours and a
fundamental tool for gene discovery. The number of cell lines
derived from poorly differentiated and ATC is small with just two
PDTC cell lines (NPA and SMP) being referred in the literature
(Asakawa et al, 1996; Ringel et al, 2000; Onda et al, 2004).
In our laboratory we were able to establish cell lines from two
PDTC and three ATC, which we evaluated by conventional
cytogenetics, CGH and oligonucleotide array analysis. It was our
aim to characterise the cell lines at chromosomal and expression
levels, providing information on the yet unknown deregulated
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sgenetic mechanisms associated to these two forms of aggressive
thyroid neoplasias, namely to identify the target genes located at
the amplicon units of the ATC cell lines.
From our results, it was evidenced that both cancer cell line
types were characterised by largely altered chromosomal and
expression profiles. In PDTC, we noted as significant the
deregulation of MAPK pathway effectors and of a group of tumour
suppressor genes. In ATC, we identified 40 genes as amplicon
targets. Comparison of array results between the two types of cell
lines revealed significant differences in the expression levels of
genes related to signal transduction, cell adhesion, and motility.
Array data were validated at RNA level through the performance
of quantitative reverse transcription-polymerase chain reaction
(RT–PCR) experiments for ARNTL2, AURKA, CDH13, CLDN1,
PLAU, PMAIP1, and RBAK.
MATERIALS AND METHODS
Tumour specimens, conventional cytogenetics and CGH
analysis
Tissue samples were obtained by thyroidectomy from two
patients with poorly differentiated papillary carcinomas and three
patients with anaplastic carcinomas. Tumours were classified
according to the criteria described in the Armed Forces Institute
of Pathology (Rosai et al, 1992) and revaluated according to
WHO histological classification of thyroid and parathyroid
tumours by DeLellis and Williams (2004). Representative haema-
toxylin–eosin tissue sections from each of the primary tumours
are shown in Figure 1A–F. A summary of the patient’s clinical and
histological data and the cell lines designation is depicted in
Table 1.
Tumour cells were grown in Rosewell Park Memorial Institute
1640 (RPMI 1640) medium (Gibco-Invitrogen, Scotland, UK),
containing 10% fetal calf serum (FCS) (Gibco-Invitrogen, Scotland,
UK) and 1% antibiotic/antimicotic solution (Sigma-Aldrich
Chemie, GmbH, Germany).
For conventional cytogenetic analysis cells were harvested after
a 3- to 5-h treatment with colchicine (Karyomax-Gibco-Invitrogen,
Scotland, UK). The metaphases obtained were GTG banded and
karyotypes described according to International System for
Human Cytogenetic Nomenclature (ISCN) (1995) (Mitelman,
1995).
Comparative genomic hybridisation of the five cell lines and
evaluation of the obtained results were performed as described
previously (Rodrigues et al, 2004).
B A
D C
F E
Figure 1 Representative haematoxylin–eosin-stained tissue sections of the primary poorly differentiated and anaplastic thyroid carcinomas from which
the cell lines were derived. (A) T235 (original amplification 100); (B) T238 (original amplification 100); (C) T241 (original amplification 100); (D) T243
(original amplification 100); (E) T243 (original amplification 400); (F) T351 (original amplification 100).
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Human thyroid total RNA from Clontech
s (consisting in a pool of
thyroid RNA obtained from 65 individuals who died from sudden
death) was used as a normal baseline reference for microarray
experiments. Total RNA from the cell lines was extracted using
Trizol
s (Gibco-Invitrogen, Scotland, UK), and cleaned up using
Quiagen columns according to manufacturer’s protocols. RNA
integrity was assessed in the Bioanalyser Agilent 2100 and by
visualisation of 28 and 18-s bands in agarose gel electrophoresis.
Ribonucleic acid concentration was determined by spectrophoto-
metry. For hybridisation the commercial GeneChip
s Human
Genome U133 Plus 2.0 Array from Affymetrix
s were used.
For each cell line a pool of RNA derived from different passages
was obtained, and samples were processed according to the
experimental procedures specified by Affymetrix
s.
The obtained microarrays were scanned in GeneChip
s Scanner
3000 from Affymetrix
s, controlled by a workstation with the
GeneChip
s Operating Software (GCOS) version 1.1.
Statistical analysis
The software chosen for the analysis was the DNA-Chip Analyser
(dChip) (copyright 2000–2004 Wang Lab, Harvard School of
Public Health and Dana-Farber Cancer Institute). In the first step
of the statistical analysis the arrays were normalised by the
invariant set normalisation method, so that all non-biological
variables were reduced, followed by a model-based expression
analysis, using the model PM-only. The genes were filtered, so that
those absent in all the samples were eliminated from the analysis.
We considered genes to be differentially expressed between
samples, when the lower bound of fold change (LBFC) was at
least 2, with a confidence of 90%. In order to determine relevant
genes overexpressed in the high-level amplification regions (HLA),
we chose the set of genes that were found to have (i) an LBFC45i n
the comparison of the cell with the HLA to normal thyroid, within
the HLA chromosomal region, and (ii) were commonly differen-
tially expressed in the comparison of the three ATC cell lines to
normal thyroid. The obtained data were then subject to
hierarchical clustering and principal components analysis (PCA).
The genes were also classified according to ‘gene ontology’ and
‘chromosome location’ using classify genes tool of D-Chip. We
regarded only the P significant genes (Po0.001) for this
classification.
Quantitative real-time RT–PCR
To validate the array results, quantitative real-time RT–PCR was
performed on seven genes: Aryl Hydrocarbon Receptor Nuclear
Translocator-like 2 (ARNTL2); Aurora Kinase A (AURKA),
Cadherin 13 (CDH13), Claudin 1 (CLDN1), phorbol-12-myristate-
13-acetate-induced protein 1 (PMAIP1), plasminogen activator
urokinase (PLAU), and RB-associated KRAB repressor (RBAK)
using an ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA, USA). Sequence-specific primers and
probes were selected from the Assay-on-Demand products
(Applied Biosystems). As endogenous control we selected the
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) from Applied Biosystems (HS:99999905_m1). The
conditions of the TaqMan
s PCR were as follows: 951C for
10min, followed by 40–45 cycles of 951C for 15s and 601C for
1min. The relative expression of each sample was calculated
with respect to a standard calibration curve that represents a serial
dilution of cDNA positive for the expression of the gene in
analysis. Each sample was analysed three times and each PCR
experiment included at least one non-template control well.
ARNTL2, AURKA, CLDN1, PMAIP1, and RBAK were chosen as
representative overexpressed genes at the HLA regions. TaqMan
s
PCR experiments were performed in the three ATC cell lines
reported herein as well as in three ATC independent primary
tumours.
CDH13 and PLAU were chosen because they were genes that
accordingly to array data allowed a clear distinction between ATC
and PDTC. Experiments were performed in the five cell lines
described herein, in 14 PDTC primary tumours and in the
previously aforementioned three ATC additional samples.
RESULTS
Conventional cytogenetic and CGH analysis
Tumours were characterised by karyotypes with both structural
and numerical abnormalities (chromosomal supplementary data).
Several populations were found in all cell lines . Different
populations presented roughly the same alterations, differing only
in ploidy. Maintenance of the karyotypes was observed for all cell
lines.
By CGH all cell lines presented multiple chromosomal
imbalances. No significant modifications were observed through-
out time at CGH level in any of the carcinomas after cell line
establishment. A summary of the CGH imbalances is depicted in
Figure 2A. Overall, gains of DNA sequences were more frequent
than losses. High-level amplification regions were observed in the
following cell lines: in T235 at regions 3q24-qter, 7q11.2-q22,
12pter-p11 and chromosome 20; in T238 at 18q21; and in T241 at
5pter-p12, 7pter-p21, 14q10-qter, and 20p11.2-qter (Figure 2B–D).
Comparative genomic hybridisation of the corresponding
primary tumours have been performed and reported previously
(Rodrigues et al, 2004). The chromosomal gains and losses
observed for each of the cell lines and respective primary tumours
were represented in an excel table (CGH supplementary data).
Analysis of these data allowed to verify that although CGH
alterations observed in the cell lines were not identical to the ones
found in primary tumours, they presented major similarities,
indicating that these cell lines largely reflect their primary tumour
major cytogenetic imbalances.
Comparison of our PDTC and ATC CGH results with previously
reported data (Hemmer et al, 1999; Wilkens et al, 2000;
Wreesmann et al, 2002; Rodrigues et al, 2004) revealed that all
imbalances, described as frequently occurring in the literature,
were also observed in the cell lines.
Oligonucleotide microarray analysis
For oligo-array analysis, only the cell lines were evaluated, owing
to lack of well-preserved samples for RNA analysis.
Our work represents the first array expression profile in PDTC.
Comparison of the gene expression profiles of the two PDTC
Table 1 Clinical and histological data of the five cancer patients
Case Sex/age
Date of
surgery Deceased Histologic diagnosis
T235 F/77 12.05.97 17.06.97 Anaplastic thyroid
carcinoma
T238 F/74 20.05.97 1.06.97 Anaplastic thyroid
carcinoma
T241 F/72 30.06.97 30.11.97 Anaplastic thyroid
carcinoma
T243 M/67 20.07.97 — Poorly differentiated
papillary thyroid carcinoma
T351 M/58 10.01.00 20.10.02 Poorly differentiated
papillary thyroid carcinoma
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Figure 2 (A) Summary of the DNA copy number changes detected by CGH. Each bar in the left side of the chromosome ideograms represents a loss in
one cell line (red—ATC, orange—PDTC) and each bar on the right side of represents a gain in one cell line (green—ATC, blue—PDTC). High-level
amplifications are represented by thicker lines. (B) T235 HLA regions at 3q24-qter, 7q11.2-q22, 12pter-p11, and 20pter-qter; (C) T238 HLA at 18q21; (D)
T241 HLA regions at 5pter-p12, 14q10-qter and 20p11.1-qter.
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(Po0.001) differentially expressed genes. In all, 1079 genes were
overexpressed and 3159 were underexpressed (array supplemen-
tary data). In Table 2 are depicted the 10 more overexpressed and
the 10 more underexpressed genes in PDTC vs normal thyroid.
After gene clustering of the differentially expressed genes
according to their cellular function, the 10 main categories were
in the order: ATP binding, cytoskeleton, cell cycle, mitosis, muscle
development, DNA replication, tumour suppressor, transmem-
brane receptor protein tyrosine kinase signalling pathway,
chromosome organisation and biogenesis, and RNA processing
(array supplementary data).
When comparing gene expression profiles of the three ATC cell
lines with normal thyroid, we found 3367 significantly (Po0.001)
differentially expressed genes. In all, 1039 genes were over-
expressed and 2328 were underexpressed (array supplementary
data).
In Table 2 are depicted the 10 more overexpressed and
underexpressed genes in ATC vs normal thyroid. In this group
of tumours, gene clustering of the differentially expressed genes
according to their cellular function revealed that the most
representative were in the order: ATP binding, transport,
extracellular space, cell growth and/or maintenance, cell adhesion
molecule activity, cytoskeleton, soluble fraction, actin binding,
extracellular matrix, and muscle development (array supplemen-
tary data). By array analysis we observed in ATC as well as in
PDTC that expression downregulation was more relevant than
upregulation, whereas by CGH gains were more frequent. A
general lack of correlation between chromosomal CGH and array
data has previously been described in other neoplasms, namely in
colon cancer (Platzer et al, 2002), and may be explained by the
recent observations demonstrating that changes in DNA copy
number induce changes in the expression of only a limited number
of genes. Moreover, the different sensitiveness of the two
techniques must also be taken into account.
Comparison between the expression levels at the HLA regions in
ATC and normal thyroid revealed that all the differentially
expressed genes mapped at these chromosomal regions were
overexpressed. In Table 3, we show the set of 40 genes identified to
be commonly overexpressed in the three cell lines and mapping at
the HLA regions. Of these, 37 represent known genes and three
were ORFs (open reading frames).
When comparing the expression profiles of the two types of cell
lines, we found 140 significantly differentially expressed genes
(Po0.001). Of these, 33 were more expressed in PDTC cell lines
and the other 107 were relatively more expressed in the ATC cell
lines (array supplementary data). Clustering of these genes
according to their cellular function revealed that the most
representative group was that of signal transduction molecules
followed by groups of genes involved in cell adhesion and motility
process (array supplementary data).
Hierarchical clustering using the 140 differentially expressed
genes allowed a clear segregation of the tumour cells (Figure 3A).
However, we could verify, when selecting only the nine more
expressed genes in ATC and in PDTC, that a clear segregation of
the two tumour types was still observable both my hierarchical
clustering (Figure 3B) and PCA analysis (Figure 3C). All these
molecules are known to be involved in cancer process, some being
identified as tumour suppressor genes (e.g. GPR54 and CLDN23)
(Kotani et al, 2001; Katoh and Katoh, 2003) and others related to
angiogenesis (e.g. CXL1 and EDNRA) (Hosoda et al, 1992; Shintani
et al, 2004) or cell migration capacities (e.g. PLAU) (Guo et al,
2002).
Quantitative real-time PCR
Regarding the genes mapped at the HLA regions, TaqMan
s PCR
experiments confirmed the overexpression noted in microarrays
analysis for all chosen genes: ARNTL2, AURKA, CLDN1, PMAIP1,
and RBAK. Of remark is that the elevated expression values of
these genes were also observed in the three additional ATC
primary samples. As for CDH13 and PLAU, TaqMan
s PCR
Table 2 List of the 10 more up- and downregulated genes in the
comparisons PDTC/normal thyroid and ATC/normal thyroid
Gene LBFC
The 10 genes more upregulated in the comparison PDTC/normal thyroid
T-LAK cell-originated protein kinase (PBK) 66.95
Prostate differentiation factor (GDF15) 43.56
Anillin, actin-binding protein (scraps homolog, Drosophila)( ANLN) 39.80
Leucine zipper protein FKSG14 (FKSG14) 31.82
Hyaluronan-mediated motility receptor (RHAMM) (HMMR) 28.71
Activin b E( INHBE) 27.29
Discs, large homolog 7 (Drosophila)( DLG7) 24.57
Thymidylate synthetase (TYMS) 24.14
Topoisomerase (DNA) II a 170kDa (TOP2A) 23.84
Asp (abnormal spindle)-like, microcephaly associated
(Drosophila)( ASPM)
23.64
The 10 genes more downregulated in the comparison PDTC/normal thyroid
Lumican (LUM)  233.11
Mucin 7, salivary (MUC7)  152
Solute carrier family 26, member 4 (SLC26A4)  133.11
Histatin 3 (HTN3)  132.01
Histatin 1 (HTN1)  122.6
Integral membrane protein 2A (ITM2A)  107.75
Statherin (STATH)  98.39
Amylase, a 2A; pancreatic (AMY2A)  93
S100 calcium-binding protein A8 (calgranulin A) (S100A8)  88.3
Homo sapiens-transcribed sequence with weak similarity to
protein ref:NP_060312.1 (H. sapiens) hypothetical protein
FLJ20489 [Homo sapiens]
 79.35
The 10 genes more upregulated in the comparison ATC/normal thyroid
Homo sapiens-transcribed sequences 54.26
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) 46.41
Fibronectin 1 (FN1) 41.06
Melanoma antigen, family A, 6 (MAGEA6) 31.36
L1 cell adhesion molecule (hydrocephalus, stenosis of aqueduct
of Sylvius 1, MASA (mental retardation, aphasia, shuffling gait and
adducted thumbs) syndrome, spastic paraplegia 1) (L1CAM)
30.98
Gb:AF043337.1 /DB_XREF¼gi:12641914 /GEN¼IL8 /
FEA¼FLmRNA /CNT¼1 /TID¼Hs.624.1 /TIER¼FL /STK¼0
/UG¼Hs.624 /LL¼3576 /DEF¼Homo sapiens interleukin 8
C-terminal variant (IL8) mRNA, complete cds. /
PROD¼interleukin 8 C-terminal variant /FL¼gb:AF043337.1
30.82
E2F transcription factor 7 (E2F7) 22.83
Human full-length cDNA 50-end of clone CS0DK007YB08 of
HeLa cells of Homo sapiens (human)
20.93
Melanoma antigen, family A, 3 (MAGEA3) 19.99
Anillin, actin-binding protein (scraps homolog, Drosophila)( ANLN) 19.74
The 10 genes more downregulated in the comparison ATC/normal thyroid
Histatin 3 (HTN3)  380.67
Solute carrier family 26, member 7 (SLC26A7)  253.51
Histatin 1 (HTN1)  198.24
Mucin 7, salivary (MUC7)  177.54
Glycine amidinotransferase (L-arginine:glycine
amidinotransferase) (GATM)
 159.71
Solute carrier family 26, member 4 (SLC26A4)  149.79
Immunoglobulin J polypeptide, linker protein for immunoglobulin
a and m polypeptides (IGJ)
 127.34
Thyroglobulin (TG)  118.95
Thyroid peroxidase (TPO)  116.25
Integral membrane protein 2A (ITM2A)  115.31
PDTC¼poorly differentiated thyroid carcinomas. ATC¼anaplastic thyroid carcino-
mas. LBFC¼lower bound of fold change.
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Whitney statistical testing of the results revealed significant
differences between the gene expression levels in the two types
of neoplasms. The obtained P-values for CDH13 was ¼0.0275 and
for PlAU was ¼0.0377.
DISCUSSION
Alterations in the structure or expression of proto-oncogenes and
tumour suppressor genes were determined to be fundamental to
cancer development and progression by respectively up- and
downregulating cellular control pathways (Vogelstein and Kinzler,
1998). In thyroid the identification of these genes and how their
alterations contribute to the pathogenesis of the two most
aggressive cancer forms: poorly differentiated and anaplastic
carcinomas are still ill defined. The use of cancer cell lines has
represented an invaluable tool for gene discovery in other tumour
types. As such, and to obtain information about the altered genes
other than those already known to be associated to these two
tumour types, we performed an evaluation at the DNA and RNA
levels using cytogenetic and oligo-array analysis in five new cell
lines established from two PDTC and three ATC.
Poorly differentiated thyroid carcinomas are classified accord-
ing to the WHO as neoplasms presenting morphological and
clinical criteria in between well-differentiated thyroid: papillary
and follicular carcinomas, and anaplastic cancers.
Chromosomal translocations, inversions and duplications are
the known mechanisms of oncogene activation in cancer. At the
cytogenetic level, the most frequent structural rearrangements in
papillary cancers are abnormalities with breakpoints at 10q11.2
(Roque et al, 2001). These alterations lead to the activation of the
RET proto-oncogene. In our PDTC cell lines, although papillary
features were still recognised, none of them presented alterations
with breakpoints at 10q11.2 (RET gene was also observed not to
be recombined – data not shown). However, of remark is the
observation that by array analysis the most significantly over-
expressed gene was PBK. The protein encoded by PBK is a serine/
threonine kinase which belongs to the MAPK kinase protein family
(Abe et al, 2000). The involvement of PBK has not previously been
observed in thyroid cancer, but previous data (Mellilo et al, 2005)
have demonstrated that the constitutive activation of effectors
along the MAPK/ERK signalling pathway display a key role in the
genesis and progression of a substantial proportion of papillary
tumours. Our array findings thus reinforce the importance of this
signalling pathway in the tumourigenesis of thyroid carcinomas
with papillary characteristics.
P53 is the only tumour suppressor gene identified to be involved
in the pathogenesis of PDTC. Molecular studies revealed, however,
that the frequency of tumours with mutations at this gene is low:
B25% of cases (Wynford-Thomas, 1997). In our study, we were
able to identify a group of other tumour suppressor genes which
were downregulated in these carcinomas, and may have a key role
in their development or progression. PLAGL1 gene, which maps at
6q24.2, and CDH1 mapping at 16q22.1, were those with the highest
LBFC, respectively,  33.87 and –7.06. The involvement of PLAGL1
has not been previously noted in PDTC. At variance, participation
of CDH1, which codes for E-cadherin in thyroid tumorigenesis
has been described. Rocha et al (2003) studied 17 cases of primary
PDTC and showed that loss of E-cadherin was a common feature of
these tumours.
In our array analysis, in the list of the 10 more underexpressed
genes in ATC, we found thyroglobulin and thyroid peroxidase.
This finding is in keeping with a preceding array study by Onda
et al (2004) in a group of 11 ATC cell lines, and confirms previous
studies demonstrating that in anaplastic tumours there is loss of
the most characteristic thyroid cellular function, that is, synthesis
of T4 and T3 hormones (Elisei et al, 1994). Known tumour
suppressor genes, although not included in this list, were noted as
downregulated in the array analysis for example, the FHIT
(LBFC¼ 5.39) at 3p14.2; ST7 (LBFC¼ 2.95) at 7q31 or CLDN23
(LBFC¼ 4.58) at 8p23.1. Our results strengthen LOH studies
(Kitamura et al, 2001) carried out in ATC that showed frequent
allele loss at multiple chromosomal sites in this carcinoma type.
Specifically interesting is the underexpression of the ST7 tumour
Table 3 Set of genes found to be commonly differentially expressed in
the comparison of the three ATC cell lines to normal thyroid
Genes
LBFC in
3ATC/NTHY
#3q
Claudin 1 (CLDN1) 19.09
Butyrylcholinesterase (BCHE) 8.59
SMC4 structural maintenance of chromosomes 4-like 1
(SMC4L1)
8.56
Epithelial cell transforming sequence 2 oncogene (ECT2) 6.85
Transferrin receptor (p90, CD71) 6.68
Karyopherin a 4 (importin a 3) (KPNA4) 4.56
BM-011 protein (BM-011) 3.18
Likely ortholog of mouse IRA1 protein (IRA1) 2.13
#5
FLJ32363 protein (FLJ32363) 3.9
#7
Activator of S-phase kinase (ASK) 8.44
Zinc finger protein 92 (HTF12) 8.01
FLJ20073 protein (FLJ20073) 7.54
Asparagine synthetase (ASNS) 6.91
RB-associated KRAB repressor (RBAK) 4.07
Hypothetical protein FLJ20097 (FLJ20097) 3.11
Origin recognition complex, subunit 5-like (yeast) (ORCL5) 2.45
Paternally expressed 10 (PEG10) 2.26
#12
RAD51-interacting protein (RAD51AP1) 5.04
Forkhead box M1 (FOXM1) 3.63
Aryl hydrocarbon receptor nuclear translocator-like 2 (ARNTL2) 2.73
#14
KIAA1333 (KIAA1333) 3.29
Suppressor of Ty 16 homolog (S. cerevisiae)( SUPT16H) 3.25
Mitogen-activated protein kinase kinase kinase kinase 5 (ASK1) 3.23
WD repeat and HMG-box DNA-binding protein 1 (WDHD1) 2.89
#18
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) 46.41
#20
Ubiquitin-conjugating enzyme E2C (UBEC2C) 11.92
Synaptosomal-associated protein, 25kDa (SNAP25) 7.14
Chromosome 20 open reading frame 97 (C20ORF97) 5.75
Aurora kinase A (AURKA) 5.62
Eukaryotic translation initiation factor 2, subunit 2 b,3 8k D a
(EIF2S2)
3.98
Syntaxin 16 (STX16) 3.92
Chromosome 20 open reading frame 6 (C20ORF6) 3.77
CGI-09 protein (CGI-09) 3.72
TPX2, microtubule-associated protein homolog (Xenopus laevis)
(TPX2)
3.56
Chromosome 20 open reading frame 100 (C20ORF100) 2.97
Phospholipase C, b 1 (phosphoinositide-specific) (PLC beta) 2.75
CSE1 chromosome segregation 1-like (yeast) (CSE1) 2.61
Solute carrier organic anion transporter family, member 4A1
(SLCO4A1)
2.58
Transglutaminase 2 (C polypeptide, protein-glutamine-
g-glutamyltransferase) (TGM2)
2.6
MCM8minichromosome maintenance deficient 8 (S. cerevisiae)
(MCM8)
2.22
ATC¼anaplastic thyroid carcinomas; HLA¼high-level amplification regions;
LBFC¼lower bound of fold change.
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been reported as frequently deleted in ATC also by previous CGH
studies (Rodrigues et al, 2004).
Gene amplification was observed to be a common phenomenon
in ATC (Roque et al, 1998). In this study we were able to define for
the first time the nature of the amplicon target genes present in
this type of carcinomas. We found a set of 40 commonly
overexpressed genes at the HLA (Table 3), which included
molecules that are known to be involved in the regulation of
centrosome duplication, chromosome orientation, and segregation
process in cells such as: AURKA, TPX2, CSE-1, MCM8 or SMC4
(Adams et al, 2001). Genes related to transcription regulation (e.g.
RBAK at 7p22.1 and ARNTL at 12p) and to cell adhesion process
like CLDN1. Noteworthy was the observation of PMAIP1 as an
amplicon target at 18q21.32. PMAIP1 is a gene expressed in cells
in response to hypoxia, allowing cell adaptation to the altered
metabolic demands induced by decreased oxygen levels (Yakovlev
et al, 2004). Kim et al (2004) demonstrated that PMAIP1 promoter
directly responds to hypoxia via the hypoxia-induced factor
(HIF1A). The b-subunit of HIF1A is ARNT. Of remark is the fact
that ARNTL2 was one of the overexpressed genes located at
12p11.3. Anaplastic thyroid carcinomas invade, infiltrate and
rapidly grow in the surrounding tissues. In this context, we suggest
that during the amplification process autocrine lopps are created
that may confer important growth advantages to the neoplasms.
The results obtained by TaqMan
s PCR for PMAIP1 and ARNTL2,
but also for AURKA, CLDN1, and RBAK demonstrated that the
amplification process of these genes is not only cell line specific,
but also occurs in primary ATC. Therefore reinforcing the im-
portance of these molecules in thyroid anaplastic characteristics.
Anaplastic thyroid carcinomas and PDTC have distinct disease
courses. The former have a dismal prognosis, whereas in PDTC the
median survival rate is 3–5 years (DeLellis and Williams, 2004).
Assuming that these biologic different behaviours are a reflection
of the deregulation of distinct molecular characteristics in each
tumour type, we addressed this hypothesis by comparing the
ATC and PDTC cell line expression profiles. We found that the
main molecular differences between them were related to signal
transduction pathways, cell adhesion and motility process, and this
involved 140 genes.
Major advances were made in the treatment of chronic myeloid
leukaemias and gastrointestinal tumours by using drugs that
directly inhibit the pathways deregulated by the BCL2-ABL fusion
gene and c-KIT mutations (Hochhaus, 2004). These genetic
alterations are usually the only aberrations in these neoplasms at
the time of diagnosis and treatment is in fact most of the times
effective. Neoplasias such as PDTC or ATC are at variance
characterised by a profound genomic instability and the currently
used therapies especially in ATC cases are useless. In our work,
hierarchical and PCA analysis allowed to verify that a group of 18
cancer genes served as a basis to differentially characterise
anaplastic and poorly differentiated thyroid carcinomas. TaqMan
s
PCR experiments performed for two of these molecules, CDH13
and PLAU, corroborated array results revealing significant
expression levels differences between the two cancer types, not
only in the cell lines, but also in an additional set of primary 14
PDTC and three ATC. Overall, our findings point out that the
molecular pathways of ARNTL2, AURKA, CDH13, CLDN1,
PMAIP1, PLAU, and RBAK should be further investigated order
to understand the mechanisms by which these genes may be linked
Figure 3 (A) Hierarchical clustering of the genes and samples using the 140 differentially expressed genes between the ATC and PDTC. Hierarchical
clustering (B) and PCA analysis (C) of the genes and samples using the 18 genes that allowed a distinction between ATC and PDTC.
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sto anaplastic therapeutic resistance and to design concerted
therapies that could improve ATC prognosis.
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